Sector ratings Monte Rosa Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-09-02 EDT			5-day change	1st Jan Change
14.22 ^USD	-0.63%		-2.34%	-9.31%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
MONTE ROSA THERAPEUTICS, INC.	1.22B	-	BB	-	-
LONZA GROUP AG	49.74B		AAA
REVOLUTION MEDICINES, INC.	44.98B	-	B	-	-
IQVIA HOLDINGS INC.	42.52B		AAA
BEONE MEDICINES AG	40.78B		-
CELLTRION, INC.	32.89B		A
ASCENDIS PHARMA A/S	17.09B	-	-	-	-
MEDPACE HOLDINGS, INC.	16.28B		BBB
EUROFINS SCIENTIFIC SE	14.4B		AA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	13.48B		AA
ICON PUBLIC LIMITED COMPANY	12.45B		AAA
TEMPUS AI, INC.	11.24B		A		-
BIO-TECHNE CORPORATION	11.32B		AA
PHARMARON BEIJING CO., LTD.	10.64B		AA
ABIVAX	10.68B	-	BBB	-	-
APOGEE THERAPEUTICS, INC.	10.19B	-	B	-	-
IONIS PHARMACEUTICALS, INC.	9.95B	-	A	-	-
KYMERA THERAPEUTICS, INC.	9.9B	-	BBB	-	-
PRAXIS PRECISION MEDICINES, INC.	9.87B	-	B	-	-
PROTAGONIST THERAPEUTICS, INC.	9.48B		BB		-
Average	18.95B		A
Weighted average by Cap.			A